Neurological research into GPR37 in neurotherapeutics reveals exciting possibilities for central nervous system medicine. Historically, researchers regarded this orphan G protein-coupled receptor primarily as a cytotoxic substrate in juvenile parkinsonism. However, recent scientific advances demonstrate that the receptor actively participates in crucial neuroprotective pathways. Clinicians and neuropharmacologists now recognize its broader physiological roles across diverse cell populations. Consequently, elucidating its pharmacology could unlock innovative disease-modifying therapies for progressive brain disorders.

The Biological Evolution of GPR37 in Neurotherapeutics

For decades, neurobiologists studied GPR37 under the designation Parkin-associated endothelin receptor-like receptor. Early cellular experiments linked its misfolding to severe endoplasmic reticulum stress and dopaminergic degeneration. However, contemporary investigations indicate that intact GPR37 supports vital neurodevelopmental and restorative functions. Specifically, the receptor coordinates oligodendrocyte differentiation and promotes central remyelination after acute brain injury. Moreover, it actively guides neuroimmune resolution by modulating microglial activation and cytokine secretion. Consequently, GPR37 preserves surrounding neurons against persistent neuroinflammatory assault and oxidative degradation.

Furthermore, GPR37 expression occurs extensively throughout human brain tissue, concentrating within dopaminergic pathways and white matter tracts. This specific anatomical distribution means that receptor dysregulation influences multiple neurological conditions beyond classic movement disorders. In particular, neuroscientists observe altered receptor dynamics in demyelinating conditions, ischemic stroke, and chronic neuroinflammatory states. Therefore, the scientific view has shifted fundamentally over recent years. Scientists no longer see the protein solely as a metabolic liability. Instead, researchers appreciate GPR37 as an essential mediator of cellular resilience, glial homeostasis, and neuronal survival in the central nervous system. Accordingly, understanding its physiologic role in cellular protection provides exciting therapeutic opportunities for neurodegenerative medicine. Moreover, ongoing translational research aims to harness these endogenous survival mechanisms to halt neurodegenerative decline.

Structural Complexity and N-Terminal Ectodomain Processing

GPR37 possesses a distinct molecular architecture that distinguishes it from canonical Class A receptors. Notably, the protein features an unusually elongated extracellular amino terminus. Metalloproteinases, particularly ADAM10, cleave this extensive N-terminal ectodomain under normal physiological conditions. In addition, proprotein convertases such as furin participate in secondary cleavage events at defined recognition motifs. This proteolytic processing significantly reshapes receptor surface availability and cellular responsiveness. As a result, native tissues express both full-length and truncated forms of the receptor simultaneously.

Consequently, the cleaved receptor exhibits marked alterations in basal signaling and constitutive activity. The released extracellular fragment, designated as ecto-GPR37, enters the surrounding extracellular milieu and cerebrospinal fluid. Furthermore, receptor cleavage directly impacts how the protein forms homomers or oligomerizes with adjacent membrane partners, including dopamine D2 receptors. Because truncated receptors display distinct conformations, they interact differently with intracellular heterotrimeric G proteins. Therefore, drug developers must evaluate which specific receptor species mediates beneficial neuroprotective actions before designing molecular interventions. Recognizing these distinct conformational states remains pivotal for rational therapeutic design.

Deorphanization Challenges and Ligand Pharmacology

Translational drug discovery targeting GPR37 faces significant hurdles due to unresolved receptor pharmacology. Over the past decade, various laboratories identified putative endogenous agonists, including prosaposin, neuroprotectin D1, and osteocalcin. However, independent research teams often encounter difficulty replicating these functional signaling responses across standardized platforms. Inconsistent assay readouts occur because GPR37 displays high constitutive activity and unpredictable cell-surface trafficking. Additionally, the presence of distinct truncated receptor variants alters agonist sensitivity in artificial expression systems. These methodological discrepancies have slowed conventional pharmacology programs considerably.

Moreover, medicinal chemists must achieve precise selectivity over the closely related paralog GPR37L1. Although GPR37 and GPR37L1 share structural homology, their physiological locations and signaling profiles diverge substantially. Astrocytes predominantly express GPR37L1, whereas neurons and oligodendrocytes express GPR37. Therefore, non-selective chemical probes risk producing off-target glial effects that complicate clinical translation. Moving forward, the field must establish standardized, disease-relevant bioassays. These modern assays will clarify exact downstream pathways, including Gi/o-coupling, extracellular signal-regulated kinase activation, and intracellular calcium mobilization in human neural models.

Ecto-GPR37 as an Emerging Parkinson's Disease Biomarker

While classical ligand pharmacology remains complex, GPR37 processing provides an immediate clinical opportunity. Clinical researchers have discovered that the cleaved extracellular domain, ecto-GPR37, circulates within human cerebrospinal fluid. Notably, clinical investigations demonstrate that ecto-GPR37 concentrations rise significantly in patients with sporadic Parkinson's disease. In contrast, patients suffering from Alzheimer's disease or atypical parkinsonian syndromes maintain normal baseline levels. Thus, ecto-GPR37 offers unique diagnostic specificity for alpha-synuclein-driven neurodegeneration, aiding differential diagnosis in ambiguous clinical scenarios.

More remarkably, recent longitudinal studies connect elevated cerebrospinal fluid ecto-GPR37 levels to disease progression rates. Patients with slow-progressing Parkinson's disease exhibit the highest concentrations of soluble ecto-GPR37 peptides. Conversely, individuals experiencing rapid motor decline show diminished cleavage fragments in their cerebrospinal fluid. This biological pattern suggests that robust N-terminal processing reflects an innate neuroprotective attempt to clear toxic full-length receptor aggregates. Consequently, clinicians may soon utilize ecto-GPR37 as a stratification biomarker. This biological tool will enable clinicians to predict individual disease trajectories, enrich clinical trial cohorts, and tailor neuroprotective regimens accordingly.

Translational Roadmaps: Chemical Biology and Beyond

Given the intricacies of GPR37 biology, traditional agonist development strategies may prove premature. Instead, leading experts advocate for chemical biology and biomarker-led drug discovery paradigms. Specifically, scientists must develop a comprehensive pharmacological toolkit that interrogates receptor processing, cell-surface trafficking, and intracellular signaling simultaneously. Novel allosteric modulators represent an exceptionally promising avenue. Unlike orthosteric agonists, positive or negative allosteric modulators fine-tune endogenous receptor activity while preserving physiological signaling patterns. Additionally, selective allosteric ligands minimize desensitization and reduce the danger of intracellular receptor accumulation, thereby preserving cellular proteostasis.

Furthermore, targeting the enzymatic machinery that controls N-terminal cleavage presents another innovative therapeutic avenue. By modulating specific proteases like ADAM10, researchers could theoretically enhance protective shedding and reduce intracellular proteostatic burden. Ultimately, combining robust biofluid biomarkers with tailored chemical probes will accelerate clinical translation in neurotherapeutics. These advanced platforms will illuminate the precise cellular contexts where receptor modulation yields maximum therapeutic efficacy. As these experimental tools mature, GPR37 will likely transition from an enigmatic orphan receptor into an actionable therapeutic anchor for neurodegenerative medicine.

Why is GPR37 considered a therapeutic target for Parkinson's disease?

GPR37 originally drew interest because its misfolded forms aggregate inside dopaminergic neurons, contributing to cellular death in juvenile parkinsonism. However, ongoing research demonstrates that normal receptor signaling actively protects mature neurons, dampens neuroinflammation, and supports myelin preservation. Furthermore, tracking receptor processing provides valuable predictive information regarding disease trajectories. Consequently, targeting GPR37 allows scientists to address core pathogenic mechanisms while utilizing its cleaved fragments as functional clinical biomarkers.

What is ecto-GPR37 and how is it used clinically?

Ecto-GPR37 represents the extracellular N-terminal fragment released from the cell membrane following specific proteolytic cleavage by metalloproteinases like ADAM10. This soluble peptide diffuses into the cerebrospinal fluid, where clinical assays can detect it. Notably, elevated cerebrospinal levels appear exclusively in patients with slow-progressing Parkinson's disease. Therefore, clinicians can utilize ecto-GPR37 as a prognostic biofluid biomarker to stratify patient risk, forecast functional decline, and personalize clinical monitoring protocols.

Why has classical ligand discovery been challenging for GPR37?

Classical ligand discovery remains challenging because GPR37 exhibits prominent constitutive signaling, intricate membrane trafficking, and extensive proteolytic remodeling. Although researchers have proposed several endogenous agonists, experimental results frequently vary across assay configurations. In addition, synthetic compounds must demonstrate strict paralog selectivity over GPR37L1, which shares considerable structural identity. Consequently, chemical biologists now prioritize developing specialized pharmacological toolkits and allosteric modulators rather than relying strictly upon conventional orthosteric screening methods.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Argerich J et al. Prospects of targeting GPR37 for neurotherapeutics. Expert Opin Ther Targets. 2026 Nov 09. doi: 10.1080/14728222.2026.2762564. PMID: 43001440.
2. Bolinger AA, Frazier A, La JH, Allen JA, Zhou J. Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target. ACS Chem Neurosci. 2023;14(18):3318-3334.
3. Liu S, Bai T, Liu X, Zhao W, Li X, Sui Y, Feng J. Role and regulatory mechanism of GPR37 in neurological diseases. Front Cell Neurosci. 2025;19:1617682.
4. Morató X, Pardo L, Argerich J, et al. Ecto-GPR37: a potential biomarker for Parkinson's disease. Transl Neurodegener. 2021;10(1):8.